Analystreport

NGM Biopharmaceuticals (NYSE: NGM) is now covered by analysts at B. Riley. They set a "buy" rating and a $24.00 price target on the stock.

NGM Biopharmaceuticals, Inc.  (NGM) 
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm Check Earnings Report